Younger age, higher body mass index and lower adiponectin concentration predict higher serum thromboxane B

Conclusions:
These results suggest that in DM2, the most important predictor of HAPR is younger age. Younger DM2 patients may therefore require total daily ASA doses higher than 75 mg, preferably as a twice-daily regimen, to achieve full therapeutic effect. Higher BMI and lower HMW adiponectin concentration were also associated with less potent ASA effect. This is the first study to demonstrate an association of lower adiponectin concentration with higher serum TXB2 level in patients treated with ASA.

Source: Cardiovascular Diabetology - August 15, 2014 Category: Cardiology Authors: Agnieszka Kaplon-CieslickaMarek PostulaMarek RosiakMichal PellerAgnieszka KondrackaAgnieszka SerafinEwa TrzeplaGrzegorz OpolskiKrzysztof Filipiak Source Type: research